School project · Delayed data · Not financial adviceTerms
SingularityViewAll companies

Stock research

FRACTYL HEALTH, INC. GUTS

Healthcare · Biotechnology

$4.42last close 2026-10-09 · market cap $58.63M · delayed data

Trailing returns

1M-42.45%
3M-53.49%
6M-21.63%
1Y-73.69%

Basis: Adjusted daily closes.

What it does

Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. It develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.

Open GUTS in the live terminal →

Valuation, cost of capital, SEC filings, ownership and more, with the source named on every figure.

Post on XLinkedInEmail

Where these figures come from

Delayed data. Not financial advice. Figures are read from the sources above at the dates shown; nothing here is a recommendation. Disclosures · All companies